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Conclusions: A high proportion of patients experienced a 
local relapse alone following treatment suggesting that 
radiotherapy alone without chemo-sensitisation does not 
achieve high rates of local control. The use of alternate 
approaches such as brachytherapy to provide a local boost 
may have merit and warrants further investigation. Despite 
this, there are some patients who achieve respectable 
relapse free survival and overall survival, but others where a 
palliative approach might be more appropriate. Further work 
needs to be done to understand the factors influencing 
patient outcomes following definitive radiotherapy. Further 
refinement in patient selection will follow with better 
understanding of radio-genomic profiling. 
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Purpose/Objective: To evaluate toxicity and outcomes of 
patients with anal canal cancer treated with 
hypofractionated radiotherapy schedule and a Simultaneous 
Integrated Boost with Helical Tomotherapy. 
Materials and Methods: From March 2009 to March 2014 41 
patients were treated with simultaneous integrated boost- 
intensity modulated radiotherapy and concurrent 
chemotherapy for anal canal squamous carcinoma. Two 
clinical target volumes were delineated, radiotherapy dose 
was adapted to disease stage: 50.6 Gy and 41.4 Gy in 23 
fractions in T1N0, 52.8 Gy and 43.2 Gy in 24 fractions in T2N0 
and 55 and 45 Gy in 25 fractions in all patients with N+ 
and/or ≥T3, prescribed to Planning Target Volume 1 and 
Planning Target Volume 2 respectively. The most common 
chemotherapy regimen was 5-fluorouracil and mitomycin 
based. 
Results: The median age was 63 years (range 32-84). 5, 10, 
11 and 14 patients were respectively in stage I, II, IIIA and 
IIIB. A complete response was achieved in 34/38 (89.4%) 
patients evaluable for outcomes, one partial response in 1 
patient, inoperable persistence of disease was observed in 1 
patient and progressive disease in 2 patients (local and 
metastatic respectively). Acute grade 3 skin and grade 3 
gastrointestinal toxicity was reported in 5% and 7.3% of 
patients, respectively; treatment breaks due to toxicity were 
required in 7.3% of patients. With a median follow up of 20 
months, the 2-year overall survival and disease free survival 
were 90.4% and 92.3%. 
Conclusions: In our experience, intensity modulated 
radiotherapy with simultaneous integrated boost is feasible 
and allows the obtainment of excellent results data in terms 
of overall survival, local control and toxicity without several 
breaks due to acute toxicity. 
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Purpose/Objective: The purpose of this study was to 
retrospectively assess the clinical outcome in anal cancer 
patients treated with curative intent chemo-radiotherapy in 
terms of local control (LC), distant metastases-free survival 
(DMFS) and overall survival (OS). 
Materials and Methods: From January 2002 to December 
2012, 125 patients were treated for anal carcinoma in our 
Department of Radiotherapy in Policlinico S. Orsola-Malpighi, 
Bologna. The treatment consisted of 3DCRT on the pelvis 
(median dose: 45 Gy /1.8 Gy) with concurrent chemotherapy 
(5-fluorouracil and Mitomycin-C). After a clinical response 
evaluation patients received a boost 2-3 weeks after the end 
of the 3D-CRT by either pulsed dose rate brachytherapy (80% 
of the patients, mean dose: 18.5 Gy) or without any 
interruption by external beam radiotherapy (20%, mean dose 
16.4 Gy) in patients with controindications to brachytherapy. 
Exclusion criteria for brachytherapy were: initial diffusion of 
cancer > 2/3 of circumpherence of anal canal, initial 
extended diffusion at the perianal skin, presence of a 
residual >5 cm in longitudinal or >1,5 cm in deepth after 3D-
CRT (first course) and the clinical controindication for 
anesthesia. LC, DMFS and OS were analyzed using Kaplan-
Meier method. A comparison of the survival curves was 
performed using long rank test (univariate analysis). 
Results: Males were 31 (25%), females 94 (75%). Median age 
was 61 years (range 37-94 years), elderly patients (over 65 
years-old) were 53 (42%). Tumor stage was T1 in 18 patients 
(14%), T2 in 45 patients (36%), T3 in 41 patients (33%), T4 in 
21 patients (17%). Nodal stage was N0 in 71 patients (57%), 
N1 in 29 (23%), N2 in 13 (10%). The histology was squamous-
cell carcinoma (78%) and non squamous-cell carcinoma (22%). 
HIV+ e HPV+ patients were 7 (6%) and 2 (2%), respectively. 
Median follow-up was 43 months (range: -132 months). The 5-
year LC rate was 83%. No significant association between 5-
year LC and clinicopathologic factors (age, T stage, N stage, 
histology, and HIV status) was recorded (p: NS). The 5-year 
DMFS was 93%. N stage was significantly correlated with 5-
year metastasis free survival (p<0.05). The 5-year OS was 
73.5%. T status was significantly associated with 5 year OS 
(p= 0.035). 
 
 
Conclusions: Our results confirmed that radiochemotherapy 
